Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus
A long-acting GLP-1 receptor agonist licensed for type-2 diabetes and obesity, with an active Phase III cognitive-endpoint trial in Alzheimer's disease (EVOKE) — the highest-profile emerging cognitive-relevance peptide of the 2020s.
Semaglutide is a licensed long-acting GLP-1 receptor agonist (Ozempic/Wegovy/Rybelsus) with an active Phase III Alzheimer's cognitive-endpoint trial (EVOKE) underway.
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Neuroprotection
- Half-life
- Approximately 7 days plasma (extended-acting formulation)
Section 1
Overview
Semaglutide is a synthetic long-acting analogue of glucagon-like peptide-1 (GLP-1), engineered for extended plasma half-life through fatty-acid modification and altered amino-acid substitution at the DPP-4 cleavage site. It is a licensed pharmaceutical (Ozempic, Wegovy, Rybelsus) for type-2 diabetes and obesity indications in the UK, EU, US, and most major jurisdictions, with a substantial post-marketing safety database from millions of patients.
The compound's relevance to cognitive research is emerging rather than established. Population-level observational data — including analyses of large databases like the US TriNetX network — have consistently shown reduced incidence of Alzheimer's disease and other dementias in semaglutide-treated diabetic populations versus comparator diabetes drugs. The mechanism-of-action rationale is plausible: GLP-1 receptor agonism has documented effects on brain glucose metabolism, insulin signalling, neuroinflammation, and BDNF expression, all of which are relevant to cognitive-decline pathophysiology.
The definitive test is the active EVOKE trial programme — two Phase III randomised placebo-controlled trials of oral semaglutide in early-symptomatic Alzheimer's disease, evaluating cognitive-endpoint effects over 24 months. Results are expected in the mid-2020s. If positive, semaglutide would be the first modern peptide-class drug to demonstrate cognitive efficacy in Alzheimer's; if negative, it would substantially close the cognitive-relevance research angle for the GLP-1 class.
Section 2
Discovery & History
- Developed by Novo Nordisk as a long-acting GLP-1 receptor agonist analogue of exenatide and liraglutide, with the specific structural modifications designed to achieve once-weekly subcutaneous dosing.
- Received FDA approval in December 2017 for type-2 diabetes (Ozempic). Subsequent approvals for obesity (Wegovy, 2021) and oral formulation (Rybelsus, 2019) expanded the clinical footprint dramatically.
- Population-level cognitive-endpoint observational data emerged from 2020 onwards, with multiple independent analyses showing reduced dementia incidence in semaglutide-treated cohorts versus diabetes-drug comparators.
- The EVOKE and EVOKE Plus Phase III Alzheimer's trials began recruitment in 2021, with primary results anticipated in the mid-2020s.
- The peptide's inclusion on this reference is provisional — its cognitive-relevance evidence base rests on population-level associations and the active Phase III trial, rather than on established mechanistic or clinical cognitive-endpoint data.
Section 3
Mechanism of Action
- 1Direct GLP-1 receptor agonism — sustained receptor activation drives multiple downstream effects across metabolic, cardiovascular, and central-nervous-system targets.
- 2Central GLP-1 receptor activation — GLP-1 receptors are expressed on multiple CNS neuronal populations including in the hippocampus, providing the anatomical substrate for direct cognitive effects.
- 3Improvement of central insulin signalling and brain glucose utilisation — the mechanism-of-action angle for Alzheimer's disease, which has been characterised as a 'type 3 diabetes' with central insulin resistance as a core pathophysiological feature.
- 4Reduction of neuroinflammation — measurable effects on microglial activation, cytokine expression, and neuroinflammatory markers in animal models and preclinical work.
- 5Induction of BDNF expression in hippocampus and cortex in animal models, providing a link to the BDNF-mediated cognitive-plasticity pathway that dominates the cognitive-peptide field.
- 6Reduction of amyloid-beta accumulation and tau-pathology markers in transgenic Alzheimer's model animals — the mechanistic scaffold for the disease-modifying-drug positioning in AD.
- 7Cardiovascular and metabolic-syndrome effects — reduced cardiovascular events, improved lipid profile, weight reduction — that indirectly reduce the vascular-and-metabolic contribution to cognitive decline.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Licensed clinical use in type-2 diabetes with substantial glycaemic-control benefits and reduced cardiovascular events.
- 2Licensed clinical use in obesity with substantial weight-reduction efficacy (~15% body-weight reduction over 68 weeks in Phase III trials).
- 3Population-level observational data supporting reduced dementia incidence in treated diabetic populations.
- 4Preclinical mechanistic support for cognitive-disease-modifying activity in Alzheimer's disease models.
- 5Active Phase III cognitive-endpoint trial programme (EVOKE) providing the definitive test in early-symptomatic AD.
- 6Substantial acute and long-term safety database from millions of licensed-indication patient-years.
- 7Cardiovascular and metabolic-syndrome benefits that indirectly reduce vascular-cognitive-impairment risk.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous injection (Ozempic, Wegovy) | 0.25 – 2.4 mg once weekly, titrated from starting dose | Once weekly | Chronic dosing in licensed indications |
| Oral (Rybelsus) | 3 – 14 mg once daily | Once daily | Chronic dosing in licensed diabetes indication |
Note: Not approved for cognitive indications. Cognitive-endpoint clinical use is investigational and confined to the active EVOKE trial programme.
Note: The oral formulation is the one being evaluated in the EVOKE cognitive-endpoint trials; the injectable and oral forms have overlapping but not identical pharmacokinetics.
Section 6
Administration Routes
- Subcutaneous once-weekly injection — the primary route in the licensed indications (Ozempic, Wegovy).
- Oral once-daily administration in the licensed indication (Rybelsus) and in the active EVOKE cognitive-endpoint trials.
- The oral formulation exploits a proprietary absorption-enhancer (SNAC / sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to achieve meaningful oral bioavailability from an otherwise gut-degraded peptide.
- No intranasal or transdermal delivery form exists in clinical use.
Section 7
Safety Profile
Commonly reported
- · Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are the most common tolerability signal and the principal reason for discontinuation.
- · Injection-site reactions with subcutaneous administration; typically mild and self-limiting.
- · Reduced appetite and satiety effects — the pharmacology behind the weight-loss indication and expected in all patients on the compound.
- · Occasional headache, fatigue, and dizziness during dose titration.
- · Mild transient effects on heart rate reported at low frequency.
Rare / theoretical
- · Acute pancreatitis — reported at low but non-zero frequency in the licensed clinical experience; requires discontinuation and clinical evaluation if suspected.
- · Gallbladder disease and cholelithiasis — increased risk related to rapid weight loss.
- · Thyroid C-cell tumours — theoretical concern from rodent carcinogenicity studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
- · Diabetic retinopathy complications reported at low frequency in the diabetes population.
- · Rare reports of severe hypoglycaemia in combination with sulphonylureas or insulin.
Contraindications
- · Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.
- · Type 1 diabetes and diabetic ketoacidosis.
- · Pregnancy and breastfeeding.
- · Severe gastrointestinal disease including severe gastroparesis.
- · Concurrent use with other GLP-1 receptor agonists — pharmacodynamic redundancy.
Section 8
UK & EU Regulatory Context
United Kingdom
Licensed in the UK for type-2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). Not licensed for cognitive indications.
European Union
Approved by the EMA for type-2 diabetes and weight management. Not approved for cognitive indications.
Section 9
Clinical Studies Summary
Semaglutide in Alzheimer's disease — EVOKE and EVOKE Plus Phase III trials
Active Phase III randomised placebo-controlled trial programme in early-symptomatic Alzheimer's disease, evaluating cognitive-endpoint effects of oral semaglutide over 24 months. The trials are the definitive test of the GLP-1 class's cognitive-therapeutic potential in AD, with primary results anticipated in the mid-2020s.
Semaglutide and dementia risk in population-level observational data
Multiple independent analyses of large healthcare databases (TriNetX and similar) reporting reduced incidence of Alzheimer's disease and other dementias in semaglutide-treated type-2 diabetes cohorts versus comparator diabetes drugs. The observational evidence base that motivated the EVOKE Phase III programme.
GLP-1 receptor agonism and central insulin signalling
Mechanistic characterisation of GLP-1 receptor expression and signalling in the CNS, demonstrating improved central insulin signalling, reduced neuroinflammation, and increased BDNF expression in preclinical models. The mechanism-of-action scaffold for the AD cognitive-therapeutic research angle.
Semaglutide cardiovascular and metabolic outcome trials (SUSTAIN, PIONEER)
Multiple large randomised trials establishing the compound's cardiovascular safety and metabolic efficacy in type-2 diabetes populations, providing the licensed-indication evidence base and the substantial post-marketing safety database.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Semaglutide for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Semaglutide from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.